2 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Withdrawn 2 |
Follow IgA Nephropathy: new trials by email Literature Review of IgA Nephropathy trials Research Report on IgA Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Blisibimod, Placebo - IgA Nephropathy | Phase 3 | Withdrawn | Anthera Pharmaceuticals | 2014-10-01 | 2015-07-30 | |
| Paricalcitol for the Treatment of Immunoglobulin A Nephropathy paricalcitol - IgA Nephropathy | Phase 3 | Withdrawn | Chinese University of Hong Kong | 2008-01-01 | 2015-08-03 |
Autoimmune Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Glomerulonephritis (2) · Immune System Diseases (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephritis (2) · Urogenital Diseases (2) · Urologic Diseases (2)
AMG623 peptibody (1) · paricalcitol (1)
Anthera Pharmaceuticals (1) · Chinese University of Hong Kong (1)
Hong Kong (1)